Novocure is devoted to advancing TTFields therapy for sufferers with good tumors. The LUNAR scientific trial is the first of four stage 3 medical trials predicted to readout by the top of 2024 learning using TTFields therapy to the treatment method of sound tumors with the brain, torso and abdomen.
At Novocure, workers have the opportunity to dream large and encourage one another being the most effective versions of themselves. Daily, we see and experience our effects.
learn more Find out more about our enterprise and our mission by means of tales about people, our colleagues, our collaborators and our tradition. Back about us our story our Management company presentation advocacy ESG external funding our therapy our merchandise Optune Gio® Optune Lua® our pipeline our pipeline novocuretrials.
learn more Find out more about our firm and our mission by means of tales about sufferers, our colleagues, our collaborators and our tradition. Again about us our story our leadership corporate presentation advocacy ESG exterior funding our therapy our solutions Optune Gio® Optune Lua® our pipeline our pipeline novocuretrials.
Are you guaranteed you would like to continue? This link will navigate you to definitely an external Site outside of Novocure.com. Terminate Proceed
D., Novocure’s Chief Science Officer. “We stay up for supporting researchers and jointly expanding comprehension of how TTFields therapy is usually useful in the remedy of those diseases.”
The LUNAR trial was intended to Consider using TTFields therapy along with normal systemic therapies for your remedy of metastatic non-little mobile lung most cancers, next development on or after platinum-dependent therapy. The trial fulfilled its Most important endpoint, demonstrating a statistically considerable and clinically meaningful extension in All round survival (OS) for individuals dealt with with TTFields and conventional systemic therapies, as well as a pronounced extension in OS for people randomized to get medical doctor’s option immune checkpoint inhibitor (ICI) along with TTFields.
About LUNAR LUNAR was a phase 3 trial testing the protection and efficiency of TTFields therapy when utilised along with ICI or docetaxel vs . ICI or docetaxel on your own for individuals with metastatic NSCLC who progressed in the course of or after platinum-based mostly therapy. The trial fulfilled its Main endpoint, exhibiting a statistically considerable and clinically significant enhancement in median OS when TTFields therapy was extra to straightforward therapies.
com investor relations Trader relations property inventory info corporate presentation SEC filings press releases company governance Occupations news and media information and media push package push releases impression gallery patient-ahead patient-ahead Get in touch with us
Clients and their families are at the guts of our mission. Our passion for earning a change from the lives of most cancers sufferers fuels us in our working day-to-working day do the job and guides us within our selection-building.
com Trader relations Trader relations home inventory information and facts corporate presentation SEC filings push releases company governance Occupations news and media information and media press kit press releases graphic gallery client-ahead patient-ahead Get in nervocure touch with us
find out more Find out more about our business and our mission through stories about people, our colleagues, our collaborators and our tradition. Back again about us our story our Management corporate presentation advocacy ESG exterior funding our therapy our merchandise Optune Gio® Optune Lua® our pipeline our pipeline novocuretrials.
Together with our people, we strive to extend survival in a number of the most aggressive sorts of cancer by creating and commercializing our impressive therapy.
We sign up for along with patients, caregivers and advocacy associates inside their dedication to redefine living with cancer.